Early reduction in painful physical symptoms is associated with improvements in long-term depression outcomes in patients treated with duloxetine

BMC Psychiatry

Ulrich Hegerl²  Hans-Peter Hundemer³  Deborah Quail⁴  Thomas Wagner³  Harald Weigmann⁵  Michael Linden¹  Edith Schneider³ 

[1] Research Group Psychosomatic Rehabilitation at the Charité, University Medicine Berlin and the Rehabilitation Centre Seehof, Teltow/Berlin, Germany;Department of Psychiatry, University of Leipzig, Germany;Lilly Deutschland GmbH, Medical Department, Bad Homburg, Germany;Dept European Medical Information Sciences, Eli Lilly and Co Ltd, Windlesham, UK;Boehringer Ingelheim Pharma GmbH & Co KG, A Medizinische Wissenschaft, Ingelheim am Rhein, Germany

关键词: duloxetine;    non-interventional study;    painful physical symptoms;    Depression;   

Others  :  1124486
DOI  :  10.1186/1471-244X-11-150

 received in 2011-03-08, accepted in 2011-09-20,  发布年份 2011

【 摘 要 】

Background

To investigate the association of the change of painful physical symptoms (PPS) after 4 weeks, with the 6-month treatment outcomes of depressive symptoms in patients treated with duloxetine in clinical practice.

Methods

Multicenter, prospective, 6-month, non-interventional study in adult outpatients with a depressive episode and starting treatment with duloxetine. Depression severity was assessed by the clinician (Inventory for Depressive Symptomatology [IDS-C]) and patient (Kurz-Skala Stimmung/Aktivierung [KUSTA]). Somatic symptoms and PPS were assessed using the patient-rated Somatic Symptom Inventory (SSI) and visual analog scales (VAS) for pain items. Association of change in PPS with outcomes of depressive symptoms was analyzed based on mean KUSTA scores (mean of items mood, activity, tension/relaxation, sleep) and achievement of a 50% reduction in the total IDS-C score after 6 months using linear and logistic regression models, respectively.

Results

Of the 4,517 patients enrolled (mean age: 52.2 years, 71.8% female), 3,320 patients (73.5%) completed the study. 80% of the patients had moderate to severe overall pain (VAS > 30 mm) at baseline. A 50% VAS overall pain reduction after 4 weeks was associated with a 13.32 points higher mean KUSTA score after 6 months, and a 50% pain reduction after 2 weeks with a 6.33 points improvement. No unexpected safety signals were detected in this naturalistic study.

Conclusion

Pain reduction after 2 and 4 weeks can be used to estimate outcomes of long-term treatment with duloxetine. PPS associated with depression have a potential role in predicting remission of depressive symptoms in clinical practice.

【 授权许可】

   
2011 Schneider et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Bair MJ, Robinson RL, Katon W, Kroenke K: Depression and pain comorbidity - A literature review. Arch Intern Med 2003, 163:2433-2445.
• [2]Claes S, De Bie J, De Bruyckere K, De Fruyt J, Demyttenaere K, Reynaert C, Sabbe B, van Heeringen C: Pain in Depression: Implications for Diagnosis and Treatment. Acta Psychiatrica Belgica 2006, 106:1-15.
• [3]Gambassi G: Pain and Depression: The egg and the chicken story revised. Arch Gerontol Geriatr Suppl 2009, 1:103-112.
• [4]Linton SJ, Bergbom S: Understanding the link between depression and pain. Scandinavian J Pain 2011, 2:47-54.
• [5]Stahl SM: Does depression hurt? J Clin Psychiatry 2002, 63:273-274.
• [6]Stahl S, Briley M: Understanding pain in depression. Hum Psychopharmacol Clin Exp 2004, 19:S9-S13.
• [7]Verma S, Gallagher RM: Evaluating and treating co-morbid pain and depression. Int Rev Psychiatry 12:103-114.
• [8]Carroll LJ, Cassidy JD, Côté P: Depression as a risk factor for onset of an episode of troublesome neck and low back pain. Pain 2004, 107:134-139.
• [9]Simon GE, VonKorff M, Piccinelli M, Fullerton C, Ormel J: An international study of the relation between somatic symptoms and depression. N Engl J Med 1999, 341:1329-1335.
• [10]Tylee A, Freeling P, Kerry S, Burns T: How does the content of consultations affect the recognition by general practitioners of major depression in women? Br J Gen Pract 1995, 45:575-578.
• [11]Kirmayer LJ, Robbins JM, Dworkind M, Yaffe MJ: Somatization and the recognition of depression and anxiety in primary care. Am J Psychiatry 1993, 150:734-741.
• [12]Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang P: The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289:3095-3105.
• [13]Bair MJ, Robinson RL, Eckert GJ, Stang PE, Croghan TW, Kroenke K: Impact of pain on depression treatment response in primary care. Psychosom Med 2004, 66:17-22.
• [14]Fava M, Mallinckrodt CH, Detke MJ, Watkin JG, Wohlreich MM: The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J Clin Psychiatry 2004, 65:521-530.
• [15]Kroenke K, Shen J, Oxman TE, Williams JW Jr, Dietrich AJ: Impact of pain on the outcomes of depression treatment: results from the RESPECT trial. Pain 2008, 134:209-215.
• [16]Karp JF, Scott J, Houck P, Reynolds CF, Kupfer DJ, Frank E: Pain predicts longer time to remission during treatment of recurrent depression. J Clin Psychiatry 2005, 66:591-597.
• [17]Demyttenaere K, Verhaeghen A, Dantchev N, Grassi L, Montejo AL, Perahia DG, Quail D, Reed C, Tylee A, Bauer M: "Caseness" for Depression and Anxiety in a Depressed Outpatient Population: Symptomatic Outcome as a Function of Baseline Diagnostic Categories. Prim Care Companion J Clin Psychiatry 2009, 11:307-315.
• [18]Greco T, Eckert G, Kroenke K: The outcome of physical symptoms with treatment of depression. J Gen Intern Med 2004, 19:813-818.
• [19]Sindrup SH, Jensen TS: Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999, 83:389-400.
• [20]Robinson MJ, Edwards SE, Iyengar S, Bymaster F, Clark M, Katon W: Depression and pain. Front Biosci 2009, 14:5031-5051.
• [21]Jann M, Slade J: Antidepressant agents for the treatment of chronic pain and depression. Pharmacotherapy 2007, 27:1571-1587.
• [22]Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao SG: A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol 2004, 19(Suppl 1):S27-S35.
• [23]Nemeroff CB, Schatzberg AF, Goldstein DJ, Detke MJ, Mallinckrodt C, Lu Y, Tran PV: Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2002, 36:106-132.
• [24]Brecht S, Courtecuisse C, Debieuvre C, Croenlein J, Desaiah D, Raskin J, Petit C, Demyttenaere K: Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial. J Clin Psychiatry 2007, 68:1707-1716.
• [25]Arnold LM, Meyers AL, Sunderajan P, Montano CB, Kass E, Trivedi M, Wohlreich MM: The effect of pain on outcomes in a trial of duloxetine treatment of major depressive disorder. Ann Clin Psychiatry 2008, 20:187-193.
• [26]Attal N, Gruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, Nurmikko T: EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010, 17:1113-1123.
• [27]Szegedi A, Jansen WT, van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME: Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry 2009, 70:344-353.
• [28]Wendt G, Binz U, Müller AA: KUSTA (Kurz-Skala Stimmung/Aktivierung): A daily self-rating scale for depressive patients. Pharmacopsychiatry 1985, 18:118-122.
• [29]Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH: The inventory of depressive symptomatology (IDS): psychometric properties. Psychol Med 1996, 26:477-486.
• [30]Hautzinger M, Bailer M: Das Inventar Depressiver Symptome. Universität Tübingen, Psychologisches Institut; 1999.
• [31]Weinstein MC, Berwick DM, Goldman PA, Murphy JM, Barsky AJ: A comparison of three psychiatric screening tests using receiver operating characteristic (ROC) analysis. Med Care 1989, 27:593-607.
• [32]Collins SL, Moore RA, McQuay HJ: The visual analogue pain intensity scale what is moderate pain in millimeters? Pain 1997, 72:95-97.
• [33]Demyttenaere K, Reed C, Quail D, Bauer M, Dantchev N, Montejo AL, Monz B, Perahia D, Tylee A, Grassi L: Presence and predictors of pain in depression: results from the FINDER study. J Affect Disord 2010, 125:53-60.
• [34]Garcia-Cebrian A, Gandhi P, Demyttenaere K, Peveler R: The association of depression and painful physical symptoms--a review of the European literature. Eur Psychiatry 2006, 21:379-388.
• [35]Poole H, White S, Blake C, Murphy M, Bramwell R: Depression in chronic pain patients: prevalence and measurement. Pain Practice 2009, 9:173-180.
• [36]Fishbain DA, Detke MJ, Wernicke J, Chappell AS, Kajdasz DK: The relationship between antidepressant and analgesic responses: findings from six placebo-controlled trials assessing the efficacy of duloxetine in patients with major depressive disorder. Curr Med Res Opin 2008, 24:3105-3115.
• [37]Lepine JP, Briley M: The epidemiology of pain in depression. Hum Psychopharmacol Clin Exp 2004, 19:S3-S7.
• [38]Tadić A, Helmreich I, Mergl R, Hautzinger M, Kohnen R, Henkel V, Hegerl U: Early improvement is a predictor of treatment outcome in patients with mild major, minor or subsyndromal depression. J Affect Dis 2010, 120:86-93.
• [39]Howland RH, Wilson MG, Kornstein SG, Clayton AH, Trivedi MH, Wohlreich MM, Fava M: Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression. Ann Clin Psychiatry 2008, 20:209-218.
• [40]Wade AG, Schlaepfer TE, Andersen HF, Kilts CD: Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD). J Psychiatr Res 2009, 43:568-575.
• [41]Katz MM, Meyers AL, Prakash A, Gaynor PJ, Houston JP: Early Symptom Change Prediction of Remission in Depression Treatment. Psychopharmacol Bull 2009, 42:1-14.
• [42]Henkel V, Seemüller F, Obermeier M, Adli M, Bauer M, Mundt C, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Mayr A, Möller HJ, Riedel M: Does early improvement triggered by antidepressants predict response/remission? - Analysis of data from a naturalistic study on a large sample of inpatients with major depression. J Affect Disord 2009, 115:439-449.
• [43]Romera I, Fernández-Pérez S, Montejo AL, Caballero F, Caballero L, Arbesú JÁ, Delgado-Cohen H, Desaiah D, Polavieja P, Gilaberte I: Generalized anxiety disorder, with or without co-morbid major depressive disorder, in primary care: prevalence of painful somatic symptoms, functioning and health status. J Affect Disord 2010, 127:160-168.
• [44]Romera I, Montejo AL, Caballero F, Caballero L, Arbesú J, Polavieja P, Desaiah D, Gilaberte I: Functional impairment related to painful physical symptoms in patients with generalized anxiety disorder with or without comorbid major depressive disorder: post hoc analysis of a cross-sectional study. BMC Psychiatry 2011, 11:69. BioMed Central Full Text